Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06640257
PHASE3

A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical study, consisting of a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 150 adult subjects with psoriatic arthritis.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial Evaluating the Efficacy and Safety of SHR-1314 Injection in Adults With Active Psoriatic Arthritis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2024-11-04

Completion Date

2026-06-30

Last Updated

2024-11-12

Healthy Volunteers

No

Interventions

DRUG

SHR-1314 injection

SHR-1314 injection

DRUG

Placebo

Placebo

Locations (1)

Huashan Hospital of the Shanghai FuDan University

Shanghai, Shanghai Municipality, China